Lorna Watson1, Brenda J Wilson, Norman Waugh. 1. Department of Public Health Medicine, Grampian Health Board, Aberdeen, UK. lorna.watson@isd.csa.scot.nhs.uk
Abstract
UNLABELLED: Pneumococcal polysaccharide vaccine is recommended in western countries for individuals at high risk of pneumococcal illness. We undertook a systematic review of randomised controlled trials of pneumococcal vaccine in adults, to determine the effects on clinical outcomes. RESULTS: In industrialised populations, no benefit was detected for outcomes other than pneumococcal bacteraemia, and this did not reach statistical significance. In non-industrial populations, clear benefit was demonstrated for mortality and all-cause pneumonia. CONCLUSION: Benefit from pneumococcal vaccination depends on the baseline risk of infection and characteristics of a given population. Evidence from randomised trials for widespread adult vaccination in industrial countries is lacking.
UNLABELLED: Pneumococcal polysaccharide vaccine is recommended in western countries for individuals at high risk of pneumococcal illness. We undertook a systematic review of randomised controlled trials of pneumococcal vaccine in adults, to determine the effects on clinical outcomes. RESULTS: In industrialised populations, no benefit was detected for outcomes other than pneumococcal bacteraemia, and this did not reach statistical significance. In non-industrial populations, clear benefit was demonstrated for mortality and all-cause pneumonia. CONCLUSION: Benefit from pneumococcal vaccination depends on the baseline risk of infection and characteristics of a given population. Evidence from randomised trials for widespread adult vaccination in industrial countries is lacking.
Authors: Nicholas A Daniels; Susan Gouveia; Daniel Null; Ginny L Gildengorin; Carla A Winston Journal: J Natl Med Assoc Date: 2006-07 Impact factor: 1.798
Authors: Angel Vila-Corcoles; Inmaculada Hospital-Guardiola; Olga Ochoa-Gondar; Cinta de Diego; Elisabet Salsench; Xavier Raga; Cruz M Fuentes-Bellido Journal: BMC Public Health Date: 2010-01-19 Impact factor: 3.295